An in vitro method for determining the progression to Alzheimer's disease in a subject having mild cognitive disorder, wherein the progression from mild cognitive disorder to Alzheimer's disease occurs over a period of 12 months or less, comprising detecting the protein markers of a biomarker panel in a blood plasma sample, that has been obtained from said subject, wherein the method comprises: a) providing a sample obtained from said subject at a test time point; b) determining the concentration of said protein markers of the biomarker panel; c) comparing the concentration of said protein markers of the biomarker panel in the sample at the test time point with reference values; wherein the test time point corresponds to time when the progression method is carried out; and wherein the concentration of said proteins in said sample is indicative of the progression in said subject; wherein the plasma biomarker panel comprises protein markers transthyretin (TTR), Clusterin, Cystatin C (CST3), Alpha-1-Acid glycoprotein (AlAcidG), Intercellular adhesion molecule 1 (ICAMl), Complement C4 (CC4), pigment epithelium derived factor (PEDF), Alphal antitrypsin (AlAT), regulated on activation, normal T cell expressed and secreted (RANTES), and Apolipoprotein C-III (ApoC3); and wherein conversion may be expected when the concentration of the markers is as following: transthyretin less (<) than 222 μ g/ml; Clusterin more (>) than 402 μ g/ml; Cystatin C less (<) than 3.21 μ g/ml; Alpha-l-Acid glycoprotein more (>) than 768.3 μ g/ml; Intercellular adhesion molecule 1 less (<) than 99.72 ng/ml; Complement C4 more (>) than 78.5 μ g/ml; pigment epithelium derived factor more (>) than 10.7 μ g/ml; Alphal antitrypsin less (<) than 9.5 μ g/ml; RANTES less (<) than 33.8 ng/ml; and Apolipoprotein C-III less (<) than 105.5 μ g/ml. a) providing a sample obtained from said subject at a test time point; b) determining the concentration of said protein markers of the biomarker panel; c) comparing the concentration of said protein markers of the biomarker panel in the sample at the test time point with reference values; wherein the test time point corresponds to time when the progression method is carried out; and wherein the concentration of said proteins in said sample is indicative of the progression in said subject; wherein the plasma biomarker panel comprises protein markers transthyretin (TTR), Clusterin, Cystatin C (CST3), Alpha-1-Acid glycoprotein (AlAcidG), Intercellular adhesion molecule 1 (ICAMl), Complement C4 (CC4), pigment epithelium derived factor (PEDF), Alphal antitrypsin (AlAT), regulated on activation, normal T cell expressed and secreted (RANTES), and Apolipoprotein C-III (ApoC3); and wherein conversion may be expected when the concentration of the markers is as following: transthyretin less (<) than 222 μ g/ml; Clusterin more (>) than 402 μ g/ml; Cystatin C less (<) than 3.21 μ g/ml; Alpha-l-Acid glycoprotein more (>) than 768.3 μ g/ml; Intercellular adhesion molecule 1 less (<) than 99.72 ng/ml; Complement C4 more (>) than 78.5 μ g/ml; pigment epithelium derived factor more (>) than 10.7 μ g/ml; Alphal antitrypsin less (<) than 9.5 μ g/ml; RANTES less (<) than 33.8 ng/ml; and Apolipoprotein C-III less (<) than 105.5 μ g/ml. <EOS>